Edwards Lifesciences exec sells 2,644 shares

Edwards Lifesciences Corp (EW) reported an insider sale by Annette Bruls, CVP, EMEACLA.

Rhea-AI Filing Summary

Edwards Lifesciences Corp (EW) reported an insider sale by Annette Bruls, CVP, EMEACLA. On 2026-08-28, she sold 2,644 shares of Common Stock at $89.98 per share in an open market or private transaction. Following this sale, she directly holds 17,984 shares of Edwards Lifesciences common stock.

Insider Trade Summary

Net Seller: 2,644 shares

Net Sell 1 txn

Insider Bruls Annette

Role CVP, EMEACLA

Sold 2,644 shs ($238K)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,644	$89.98	$238K

Holdings After Transaction: Common Stock — 17,984 shares (Direct)

Key Figures

Shares sold: 2,644 shares Sale price per share: $89.98 per share Shares owned after transaction: 17,984 shares

3 metrics

Shares sold 2,644 shares Common Stock sold on 2026-08-28 by Annette Bruls

Sale price per share $89.98 per share Price for the 2026-08-28 Common Stock sale

Shares owned after transaction 17,984 shares Direct Common Stock ownership of Annette Bruls after the sale

Key Terms

beneficial ownership, Common Stock, non-derivative, open market or private transaction

4 terms

beneficial ownership financial

"This Form 4 reflects changes in beneficial ownership only"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

Common Stock financial

"security_title: "Common Stock" for the reported transaction"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

non-derivative financial

"transaction_type: "non-derivative" describing the Common Stock sale"

open market or private transaction financial

"transaction_code_description: "Sale in open market or private transaction""

FAQ

Who is the insider involved in this EW Form 4 filing?

The insider is Annette Bruls, who serves as CVP, EMEACLA at Edwards Lifesciences Corp. The filing reports changes in her beneficial ownership of the company’s common stock.

How many EW shares did Annette Bruls sell in this transaction?

Annette Bruls sold 2,644 shares of Edwards Lifesciences Corp common stock. The transaction date was 2026-08-28, and it was reported as a sale of non-derivative Common Stock.

What was the sale price per share for the EW stock transaction?

The reported sale price was $89.98 per share of Edwards Lifesciences Corp common stock. The price is identified as a per-share amount for this open market or private transaction.

How many EW shares does Annette Bruls hold after this sale?

After the reported sale, Annette Bruls directly holds 17,984 shares of Edwards Lifesciences Corp common stock. The filing notes these as direct holdings following the transaction.

Was this EW insider sale made under a Rule 10b5-1 trading plan?

No. The Form 4 indicates the Rule 10b5-1 checkbox is not checked (aff_10b5_one is false), so the transaction is not affirmed as made under a Rule 10b5-1 trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/28/2026 - 04:33 PM Accepted by SEC EDGAR 08/28/2026 - 04:32 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bruls Annette

(Last) (First) (Middle)

ONE EDWARDS WAY

(Street)

IRVINE CALIFORNIA 92614

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Edwards Lifesciences Corp [ EW ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CVP, EMEACLA

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/28/2026		S		2,644	D	$89.98	17,984	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.

	Linda J. Park, Attorney-in-Fact	08/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)